Site-directed M2 proton channel inhibitors enable synergistic combination therapy for rimantadine-resistant pandemic influenza
C. Scott, J. Kankanala, T. L. Foster, D. Goldhill, K. J. Simmons, M. Pingen, M. J. Bentham, E. Atkins, E.-A. Loundras, R. Elderfield, J. K. Claridge, J. Thompson, R. Stilwell, R. Tathineni, C. S. McKimmie, , S. Griffin
The paper identifies M2-N31 inhibitors that show synergistic antiviral effects when combined with existing drugs, offering a strategy to combat rimantadine-resistant influenza.
bioRxiv · Jul 24, 2019Microbiology